EUVIMEDEUVIMED entdecken
Crossref

Novel Sulfonylurea-Based NLRP3 Inflammasome Inhibitor for Efficient Treatment of Nonalcoholic Steatohepatitis, Endotoxic Shock, and Colitis

Zhuoyue Li, Yiming Chen, Xiaolin Jiang, Penghui Lu, Chengli Wang, Zhimin Li, Xinyue Yu, Zixuan Yang, Shumin Ma, Shanshan Du, Zhengfu Tai, Xiaoyang Li iD und 3 weitere

Journal of Medicinal Chemistry · 28.09.2023 · 66 (18) · 12966-12989

DOI: 10.1021/acs.jmedchem.3c00894 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 11.09.2023. Verfasst von Zhuoyue Li und 14 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Marine Drugs, Chinese Ministry of Education, School of Medicine and Pharmacy, Ocean University of China, Qingdao 266003, China. Hauptthemen laut MEDLINE: Non-alcoholic Fatty Liver Disease, Shock, Septic, Colitis. Die Arbeit wurde bisher 39-mal zitiert (Crossref) und nennt 52 Literaturangaben. Gefördert von: Taishan Scholar Foundation of Shandong Province, Fundamental Research Funds for the Central Universities, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The NLRP3 inflammasome is a critical component of innate immunity involved in the pathophysiology of various inflammatory diseases. In this study, we designed and synthesized a series of NLRP3 inflammasome inhibitors based on MCC950. Specifically, we optimized the furan moiety, which is considered to be potentially associated with drug-induced liver injury. The representative inhibitor N14, 4-(2-(dimethylamino)ethyl)-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)benzenesulfonamide, not only maintains the NLRP3 inhibitory activity of MCC950 with IC50 of 25 nM but also demonstrates improved tolerability in human hepatic cells line and mouse primary hepatocytes. In addition, N14 exhibits superior pharmacokinetic properties, with an oral bioavailability of 85.2%. In vivo studies demonstrate that N14 is more effective than MCC950 in multiple NLRP3-related animal model diseases, including nonalcoholic steatohepatitis, lethal septic shock, and colitis. Our research has provided a lead compound that directly targets the NLRP3 inflammasome and can be developed as a novel therapeutic candidate for NLRP3-driven diseases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Non-alcoholic Fatty Liver DiseaseShock, SepticColitisMiceAnimalsHumansInflammasomesNLR Family, Pyrin Domain-Containing 3 ProteinSulfonesSulfonylurea CompoundsMice, Inbred C57BLFurans

Substanzen

InflammasomesNLR Family, Pyrin Domain-Containing 3 ProteinSulfonesSulfonylurea CompoundsFurans

Autor:innen und Institutionen

  • Key Laboratory of Marine Drugs, Chinese Ministry of Education, School of Medicine and Pharmacy, Ocean University of China, Qingdao 266003, China.
  • Center for Targeted Protein Degradation and Drug Discovery, Ocean University of China, Qingdao, Shandong 266003, China.
  • College of Chemical Engineering, Qingdao University of Science and Technology, Qingdao 266042, China.
  • Laboratory for Marine Drugs and Bioproducts, Qingdao National Laboratory for Marine Science and Technology, Qingdao 266003, China.

ORCID-Profile: Xiaoyang Li, Yuqi Jiang, Chong Qin

Förderung

  • Taishan Scholar Foundation of Shandong Province
  • Fundamental Research Funds for the Central Universities
  • National Natural Science Foundation of China

Zitieren

APA

Li, Z., Chen, Y., Jiang, X., Lu, P., Wang, C., Li, Z., Yu, X., Yang, Z., Ma, S., Du, S., Tai, Z., Li, X., Zhang, S., Jiang, Y., & Qin, C. (2023). Novel Sulfonylurea-Based NLRP3 Inflammasome Inhibitor for Efficient Treatment of Nonalcoholic Steatohepatitis, Endotoxic Shock, and Colitis. Journal of Medicinal Chemistry, 66(18), 12966-12989. https://doi.org/10.1021/acs.jmedchem.3c00894

Vancouver

Li Z, Chen Y, Jiang X, Lu P, Wang C, Li Z, et al. Novel Sulfonylurea-Based NLRP3 Inflammasome Inhibitor for Efficient Treatment of Nonalcoholic Steatohepatitis, Endotoxic Shock, and Colitis. Journal of Medicinal Chemistry. 2023;66(18):12966-12989. doi:10.1021/acs.jmedchem.3c00894

BibTeX
@article{Li2023,
  author = {Li, Zhuoyue and Chen, Yiming and Jiang, Xiaolin and Lu, Penghui and Wang, Chengli and Li, Zhimin and Yu, Xinyue and Yang, Zixuan and Ma, Shumin and Du, Shanshan and Tai, Zhengfu and Li, Xiaoyang and Zhang, Siqi and Jiang, Yuqi and Qin, Chong},
  title = {Novel Sulfonylurea-Based NLRP3 Inflammasome Inhibitor for Efficient Treatment of Nonalcoholic Steatohepatitis, Endotoxic Shock, and Colitis},
  journal = {Journal of Medicinal Chemistry},
  year = {2023},
  volume = {66},
  number = {18},
  pages = {12966--12989},
  doi = {10.1021/acs.jmedchem.3c00894}
}
Kostenlos starten →